Greenwich LifeSciences, Inc.

GLSI

US3968791083

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 13/07/2024 am IST			5-day change	1st Jan Change
15.63 ^USD	-0.95%		-6.46%	+48.57%

01/07	Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell Small Cap Completeness Index	CI
01/07	Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2000 Index	CI

Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2000 Dynamic Index

July 01, 2024

Latest news about Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell Small Cap Completeness Index	01/07	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2000 Index	01/07	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 3000E Index	01/07	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 3000 Growth Index	01/07	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 3000E Growth Index	01/07	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2000 Growth Index	01/07	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2000 Dynamic Index	01/07	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2500 Growth Index	01/07	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell Small Cap Comp Growth Index	01/07	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 2500 Index	01/07	CI
Greenwich LifeSciences, Inc.(NasdaqCM:GLSI) added to Russell 3000 Index	01/07	CI
Greenwich LifeSciences to Join Russell 2000 Index; Shares Rise	26/06	MT
Greenwich Lifesciences Insider Bought Shares Worth $2,499,998, According to a Recent SEC Filing	17/06	MT
Greenwich LifeSciences' CEO Acquires $2.5 Million in Shares	14/06	MT
Greenwich LifeSciences, Inc. announced that it expects to receive $2.499998 million in funding	13/06	CI
Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	21/05	CI
Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04	CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11/04	DJ
Greenwich Lifesciences Insider Bought Shares Worth $380,945, According to a Recent SEC Filing	07/03	MT
Greenwich LifeSciences Secures Approval to Expand GLSI-100's Phase 3 Trial to Europe	22/02	MT
Greenwich Lifesciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators	22/02	CI
HC Wainwright Adjusts Greenwich LifeSciences Price Target to $36 From $38, Maintains Buy Rating	20/02	MT
Greenwich LifeSciences, Inc. Provides Update on Phase III Clinical Trial, Flamingo-01	15/02	CI
Sector Update: Health Care Stocks Rise in Afternoon Trading	15/02	MT
Greenwich LifeSciences Shares Surge on Planned Regulatory Filing of Breast Cancer Treatment	15/02	MT

Chart Greenwich LifeSciences, Inc.

Duration

Period

More charts

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. It has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.63 USD

Average target price

36 USD

Spread / Average Target

+130.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GREENWICH LIFESCIENCES, INC.	+48.57%	201M
CSL LIMITED	+6.96%	101B
SAMSUNG BIOLOGICS CO.,LTD.	+8.29%	42.63B
UCB	+82.32%	29.77B
BIOMARIN PHARMACEUTICAL INC.	-11.82%	16.14B
INCYTE CORPORATION	+1.39%	14.31B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.13%	11.55B
ALTEOGEN INC.	+176.65%	10.53B
SWEDISH ORPHAN BIOVITRUM AB	+6.74%	9.2B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-55.52%	8.98B

Biopharmaceuticals